Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLU-Q-PAN H7N9 Formulation 3 + AS03A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This product is a **combination pandemic influenza vaccine** consisting of an inactivated, split-virion H7N9 influenza antigen (FLU-Q-PAN H7N9 Formulation 3) mixed with the **AS03A oil-in-water adjuvant system**. The vaccine is designed for enhanced immunogenicity against avian influenza A(H7N9), a virus with pandemic potential. The inclusion of the AS03A adjuvant significantly improves the body's immune response to the otherwise poorly immunogenic H7 hemagglutinin antigen. The adjuvant (AS03A) contains squalene, DL-α-tocopherol, and polysorbate 80, and is known to broaden and augment the antibody response to the vaccine. The primary indication is the **prophylaxis of influenza A(H7N9) infection** in adults and children. This vaccine formulation is designed to be mixed at the point of use, allowing for rapid deployment during a pandemic.
- Brand names
- FLU-Q-PAN H7N9 Formulation 3 + AS03A
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on FLU-Q-PAN H7N9 Formulation 3 + AS03A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLU-Q-PAN H7N9 Formulation 3 + AS03A.